Business
Key new hires to drive commercialization strategy
Key new hires to drive commercialization strategy.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9511A\n Renalytix AI PLC\n 07 June 2021\n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment\n \n \n \n \n \n Enabling expertise in sales, population health and value-driven care models\n \n \n \n \n \n \n NEW YORK and SALT LAKE CITY, June 7, 2021 -\n \n \n \n Renalytix AI plc\n \n \n (LSE: RENX) (NASDAQ: RNLX) announces a series of key hires to drive its commercialization strategy in the United States market in light of the recently announced Federal Government General Service Administration payment contract and additional large healthcare system partnerships. The combined background and experience of the new leadership team is expected to drive adoption of the KidneyIntelX testing and care model implementation in early-stage diabetic kidney disease populations. Renalytix expects to continue expanding its sales, marketing, and implementation teams with expected KidneyIntelX roll-out beginning in the VA Medical Health System in the 2nd half of 2021, and as the Company positions for a broader national expansion beginning in fiscal 2022 in line with expectations for a national Medicare insurance coverage determination later this year.\n \n \n \n \n \n Renalytix welcomes:\n \n \n \n \n \n \n Missy Martin-Kemp \n \n will join Renalytix in June as Vice President of Sales, Eastern U.S. Missy will recruit and lead a team of sales representatives focused on supporting primary care physician (PCP) and specialist practices utilizing KidneyIntelX testing as part of health system, government, and payor collaborations. She will also develop the recruiting, training, and management systems for deploying a broader sales team in 2022. Missy brings over 15 years of sales and sales leadership experience to Renalytix, with 10 of those years focused on primary care. Most recently, she served as the Chief Commercial Officer at Fibronostics. Prior to Fibronostics, Missy held multiple sales and business development leadership roles at CardioDx, a pioneer in Cardiovascular genomics. At CardioDx she led efforts to deploy their laboratory tests in private health systems and VA Centers and regional networks (VISNs). She ...